Safety Study of TXA127 to Elevate CD4+ T-Lymphocyte Counts in HIV-Infected Patients on Stable HAART Therapy
Status:
Terminated
Trial end date:
2011-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to test the safety of an investigational medication, TXA127, and
its ability to increase T-lymphocyte counts, specifically CD4+ T-lymphocytes, in persons
infected with human immunodeficiency virus who are taking highly active anti-retroviral
therapy.